Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.
Article activity feed
-
-
SciScore for 10.1101/2021.12.22.21268217: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources No participants had clinical history of COVID-19 infection, and those with laboratory evidence of prior infection, as demonstrated by presence of SARS-CoV-2 nucleocapsid antibodies, were excluded. SARS-CoV-2 nucleocapsid antibodies,suggested: NoneThe primary outcome was total serum SARS-CoV-2 anti-spike IgG antibody concentrations following a third dose compared to antibody concentrations following the two-dose series in the IBD cohort. anti-spike IgGsuggested: NoneSpecific antibodies measured in sera were nucleocapsid … SciScore for 10.1101/2021.12.22.21268217: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources No participants had clinical history of COVID-19 infection, and those with laboratory evidence of prior infection, as demonstrated by presence of SARS-CoV-2 nucleocapsid antibodies, were excluded. SARS-CoV-2 nucleocapsid antibodies,suggested: NoneThe primary outcome was total serum SARS-CoV-2 anti-spike IgG antibody concentrations following a third dose compared to antibody concentrations following the two-dose series in the IBD cohort. anti-spike IgGsuggested: NoneSpecific antibodies measured in sera were nucleocapsid and spike protein S1 receptor-binding domain (RDB)-specific IgG antibodies reported as mcg/ml as previously described. RDB)-specific IgGsuggested: None2 In patients with IBD, we measured antibody concentrations 28–35 days (t1) after completion of the two-dose series and 28–65 days (t2) after the third dose. t1suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
